Silk Road Medical Inc
Change company Symbol lookup
Select an option...
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
WPC WP Carey Inc
ATCO-I Atlas Corp
ATLX Atlas Lithium Corp
SRRK Scholar Rock Holding Corp
SCLX Scilex Holding Co
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Closing Price
$55.57
Day's Change
1.21 (2.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
55.90
Day's Low
54.00
Volume
(Below Average)
Volume:
264,483

10-day average volume:
306,620
264,483

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

4:00 pm ET November 28, 2022 (PR Newswire) Print

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to beone ofthe world'sleadingindependent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgenis one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

For more information, visitAmgen.comand follow us onTwitter, LinkedIn, Instagram, TikTokand YouTube.

CONTACT: Amgen, Thousand Oaks Jessica Akopyan, 805-447-0974 (media)Arvind Sood, 805-447-1060 (investors)

https://mma.prnewswire.com/media/152881/amgen_logo.jpg

https://c212.net/c/img/favicon.png?sn=LA48437&sd=2022-11-28

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-wcirdc-2022-301688142.html

SOURCE Amgen

https://rt.newswire.ca/rt.gif?NewsItemId=LA48437&Transmission_Id=202211281600PR_NEWS_USPR_____LA48437&DateId=20221128

comtex tracking

COMTEX_419882572/1005/2022-11-28T16:00:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.